UNCY — Unicycive Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1766140 ·
Last close
$7.06
Market Cap
$188.50M
52W High
$8.74
52W Low
$6.05
ADV30
589,121
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -8,437,000 | -12,823,000 | 64,406,000 | 37,371,000 | 26,702,000 |
| Dec 2025 | 0 | — | -7,224,000 | -14,668,000 | 49,135,000 | 29,198,000 | 18,938,000 |
| Sep 2025 | 0 | — | -7,342,000 | -6,011,000 | 50,611,000 | 42,695,000 | 13,131,000 |
| Jun 2025 | 0 | — | -6,963,000 | -6,447,000 | 29,995,000 | 22,327,000 | 13,566,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-31,317,000
Investing CF
$-12,095,000
Financing CF
$46,468,000
CapEx
$-46,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.81
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-127,825,000
Inventory
—
Receivables
—
ST Investments
$12,071,000
EBIT TTM
$-26,486,000
Pretax Income TTM
$-26,556,000
Interest Exp TTM
$70,000
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,517,000 | -26,555,000 | 49,135,000 | 18,938,000 | — | -31,317,000 |
| Dec 2024 | 0 | -32,117,000 | -36,729,000 | 31,668,000 | 24,237,000 | — | -28,575,000 |
| Dec 2023 | 675,000 | -20,774,000 | -30,544,000 | 14,191,000 | 18,000,000 | — | -18,283,000 |
| Dec 2022 | 951,000 | -18,052,000 | -18,058,000 | 2,818,000 | 3,284,000 | — | -15,651,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$6.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RNAC | Cartesian Therapeutics, Inc. | $189.51M | $6.45 | — |
| ELTX | Elicio Therapeutics, Inc. | $191.43M | $10.03 | — |
| TLSA | Tiziana Life Sciences Ltd | $192.16M | $1.51 | — |
| GALT | GALECTIN THERAPEUTICS INC | $183.74M | $2.79 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $180.05M | $4.80 | — |
News headlines (Yahoo Finance, 1h cache)
Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?
2026-05-14 23:19 · Yahoo
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 11:05 · Yahoo
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-09 11:05 · Yahoo
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
2026-03-30 11:05 · Yahoo
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
2026-02-04 12:05 · Yahoo
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
2026-01-29 14:15 · Yahoo
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
2026-01-29 12:05 · Yahoo
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
2025-12-29 12:05 · Yahoo
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth
2025-12-29 12:02 · Yahoo
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
2025-11-25 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.